Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sirnaomics Releases Positive Interim Data from Phase II Trial of siRNA Candidate

publication date: Apr 9, 2020

Sirnaomics, a US-China RNAi therapeutics company, reported positive interim results from a Phase II trial of its RNA treatment for non-melanoma skin cancer. STP705 is a siRNA (small interfering RNA) candidate that produced a complete histologic clearance of squamous cell carcinoma in situ (isSCC) in ten of fifteen patients. The candidate uses a polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-β1 and COX-2 gene expression. The results came from the first three cohorts of a US Phase II dose-escalation trial. Sirnaomics is headquartered in Maryland with subsidiaries in Suzhou and Guangzhou. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital